Accendra Health, Inc.
NYSE:ACHMedical - Distribution
+$0.12 today
- Market cap
- $54.22M
- Beta
- 1.63
- P/E (TTM)
- -0.2
- EPS (TTM)
- -$14.11
Volume 1.41M
Average 0.83M
ACH Selling, General & Admin
Overhead costs of running the business, including sales, marketing, management, and administrative staff.
Accendra Health, Inc.NYSE: ACH
Selling, General & Admin · Q1 FY2026 · quarter ended Mar 2026
Selling, general & admin declines year over year
Q1 FY2026 selling, general & admin of $251.37M fell 45.6% year over year, behind the -31.2% change in trailing-twelve-month selling, general & admin. Sequentially, it fell 6.4% from the prior quarter. Over 3 fiscal years it compounded at -12.2% a year.
Context
- Selling, general & admin amounted to 38.2% of revenue in FY2025, up 20.3 pp from a year earlier.
- Selling, general & admin increased in 2 of the last 3 fiscal years.
- FY2025 was the lowest annual figure in the 4 fiscal years shown.
What to watch
Whether selling, general & admin reaches the consensus estimate from 4 analysts of $502.04M (-52.4%) for the fiscal year ending Dec 2026, a slowdown from the -44.8% reported in FY2025.
Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterMar 2026
- $251.37M-6.4% QoQ
- Last fiscal yearDec 2025
- $1.05B-44.8% YoY
- LTMMar 2026
- $1.03B-31.2% YoY
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
Selling, General & Admin history
USD · from the income statement
- Latest · FY2025
- 1.05B USD
- Year-over-year change
- -44.8%
- 4-year CAGR
- -0.5%
| Period | Period end | Selling, General & Admin | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 1.05B | -44.8% |
| FY2024 | 2024-12-31 | 1.91B | +5.3% |
| FY2023 | 2023-12-31 | 1.81B | +16.6% |
| FY2022 | 2022-12-31 | 1.55B | +44.4% |
| FY2021 | 2021-12-31 | 1.08B | — |
Selling, General & Admin vs competitors
How ACH compares with its peers on the latest reported figures
- Peers report in different currencies, so selling, general & admin is compared through growth and share of revenue rather than absolute size.
- Its year-over-year change of -31.2% is the lowest of 11, against a peer median of -6.3%.
- Selling, general & admin amounts to 37.9% of revenue for ACH, versus a peer median of 117.9%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $1.03B USD | -31.2% | -12.2% | 37.9% | |
| LTM Mar 2026 | CA$134.01M CAD | +10.1% | -9.2% | 42.9% | |
| LTM Mar 2026 | $93.67M USD | -9.1% | -10.8% | 79.7% | |
| LTM Mar 2026 | $91.48M USD | -7.4% | -9.4% | 115.0% | |
| LTM Apr 2026 | CA$90.78M CAD | -15.3% | +7.8% | 13.5% | |
| LTM Mar 2026 | $88.81M USD | +5.3% | +20.9% | 150.3% | |
| LTM Mar 2026 | $55.88M USD | -11.2% | -10.5% | — | |
| LTM Mar 2026 | $46.76M USD | -29.2% | -11.0% | 120.9% | |
BIOABioAge Labs, Inc. | LTM Mar 2026 | $28.7M USD | +27.8% | +43.3% | 278.2% |
| LTM Mar 2026 | $28.39M USD | -5.3% | +25.8% | — | |
| LTM Mar 2026 | $22.58M USD | +5.5% | -4.4% | 269.8% | |
| Peer median (excluding ACH) | — | -6.3% | -6.8% | 117.9% | |
Competitors are the stored peer set for ACH. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 9.79B | 9.96B | 10.33B | 10.7B | 2.76B |
| Cost of Revenue | 8.27B | 8.13B | 8.21B | 8.48B | 1.56B |
| Gross Profit | 1.51B | 1.83B | 2.13B | 2.22B | 1.2B |
| Gross Margin | 15.5% | 18.3% | 20.6% | 20.7% | 43.5% |
| Research & Development | 12.1M | 0 | 0 | 0 | 0 |
| Selling, General & Admin | 1.08B | 1.55B | 1.81B | 1.91B | 1.05B |
| Operating Expenses | 1.14B | 1.68B | 2.02B | 2.43B | 1.05B |
| Depreciation & Amortization | 90.62M | 228.67M | 287.38M | 264.78M | 214.52M |
| EBITDA | 415.47M | 368.45M | 390.57M | 51.22M | 364.68M |
| EBITDA Margin | 4.2% | 3.7% | 3.8% | 0.5% | 13.2% |
| Operating Income | 368.47M | 142.91M | 104.51M | (207.77M) | 150.16M |
| Operating Margin | 3.8% | 1.4% | 1.0% | -1.9% | 5.4% |
| Interest Income | 0 | 0 | 0 | 0 | 0 |
| Interest Expense | 48.09M | 128.89M | 157.92M | 143.8M | 129.2M |
| Other Income / Expenses | (91.72M) | (132.02M) | (159.23M) | (149.59M) | (252.11M) |
| Income Before Tax | 276.75M | 10.89M | (54.73M) | (357.36M) | (101.95M) |
| Pre-Tax Margin | 2.8% | 0.1% | -0.5% | -3.3% | -3.7% |
| Income Tax Expense | 55.17M | (11.5M) | (13.43M) | 5.33M | 729K |
| Net Income | 221.59M | 22.39M | (41.3M) | (362.69M) | (1.1B) |
| Net Margin | 2.3% | 0.2% | -0.4% | -3.4% | -39.8% |
| EPS (Basic) | 3.05 | 0.30 | (0.54) | (4.73) | (14.31) |
| EPS (Diluted) | 2.94 | 0.29 | (0.54) | (4.73) | (14.31) |
| Weighted Avg Shares | 72.74M | 74.5M | 75.79M | 76.74M | 76.9M |
| Weighted Avg Shares (Diluted) | 75.49M | 76.22M | 75.79M | 76.74M | 76.9M |
Accendra Health, Inc.
NYSE:ACH
Intrinsic Alpha fair value
Locked
Current Price
$0.71
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.